Products
Ziprasidone is commercially available in capsule form (Zeldox, Geodon, generics) and other forms. It has not yet been registered in many countries. It was first approved in the United States in 2001.
Structure and properties
Ziprasidone (C21H21ClN4OS, Mr = 412.9 g/mol) is present in the capsules as ziprasidone hydrochloride monohydrate, a white to light pink powder. In other dosage forms (solution for injection), it is also present as ziprasidone mesilate trihydrate. Ziprasidone is structurally related to lurasidone.
Effects
Ziprasidone (ATC NO5AE04) has antipsychotic properties. The effects are attributed to antagonism at dopamine D2 receptors and serotonin 5HT2A receptors. The half-life is approximately 6 hours. Lurasidone has a longer half-life and therefore only needs to be taken once daily.
Indications
- For the treatment of schizophrenia.
- Manic or mixed episodes in bipolar disorder.
Dosage
According to the professional information. The capsules are usually taken twice daily with a meal.
Contraindications
For complete precautions, see the drug label.
Interactions
Ziprasidone is metabolized primarily by CYP3A4 and corresponding drug-drug interactions are possible. Ziprasidone should not be combined with drugs that prolong the QT interval.
Adverse Effects
The most common possible adverse effects include:
- Drowsiness
- Respiratory infections
- Extrapyramidal symptoms, gait disturbances, weakness.
- Dizziness, headache
- Visual disturbances
- Vomiting
